QJM Advance Access published online on July 30, 2007
QJM, doi:10.1093/qjmed/hcm065
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The effect of hormone replacement therapy on cognitive function in post-menopausal women
From the 1Gaucher Clinic, Shaare Zedek Medical Center, Jerusalem, 2NeuroTrax Corporation, Teaneck, USA, and 3Department of Obstetrics and Gynecology, Hebrew University–Hadassah Medical Center, Mt Scopus, Jerusalem, Israel
Address correspondence to Dr D. Elstein, Gaucher Clinic, Shaare Zedek Medical Center, One Bazak Road, Jerusalem 91031, Israel. email: elstein{at}szmc.org.il
Received 6 March 2007 and in revised form 24 May 2007
| Abstract |
|---|
Background: Despite interest in causes of dementia in older persons, particularly in post-menopausal women, it is unclear whether hormone replacement therapy (HRT) is a risk factor.
Aim: To assess cognitive function in post-menopausal women with high educational status receiving HRT, compared to non-users.
Design: Cognitive functioning was assessed with in women aged 55–60 years with at least university-level education, using the Mindstreams system, a computerized cognitive battery with multiple domains.
Results: Of 165 women meeting the inclusion/exclusion criteria, 82 women (49.7%) declined participation. Of the remaining 83, 40 (48.2%) had never received HRT; the remainder was divided into women receiving 5–9 years HRT (n = 29)versus those with
10 years HRT (n = 11). There were no statistically significant differences between HRT users and non-users in global scores or sub-domains of cognitive functioning, and no difference between those women receiving HRT for 5–9 years vs.
10 years.
Discussions: Long-term HRT does not appear to impair cognitive functioning in highly-educated women. Recommendations regarding post-menopausal HRT should be made on an individual basis.